New guidelines on naming and interchangeability from the Food and Drug Administration point to a changing role for biosimilars, while some of the Trump Administration's policy priorities, if implemented, could alter the dimensions of the American market.
Join The Atlantic as we gather key stakeholders to examine the future for biosimilars domestically and abroad. What impact will the President's policies have on the industry? Will changes in regulation affect how many biosimilars are approved, and what impact will these have on ensuring that these drugs are safe and accessible for the patients who need them?
8:00 am — Guest Arrival and Networking Breakfast
8:30 am — Program Begins
10:00 am — Program Concludes
Knight Broadcast Studio
555 Pennsylvania Avenue, NW
Washington, DC 20001
For more information, please contact Carly Spraggins at firstname.lastname@example.org
Also in This Series
The Next Drugs:
An Atlantic Policy Briefing on Biosimilars
The Atlantic will gather key stakeholders to examine the emerging world of biosimilars and their regulatory framework in the United States.
We The People
Featuring Georgetown University's
John J. DeGioia and
The Atlantic's Steve Clemons
In a series of conversations, The Atlantic will explore civitas, the contract binding all citizens together.
The Formative Years: What's Next for Early Care and Education? An Atlantic Next America Forum
In this Next America forum, The Atlantic will convene key policymakers, local officials, stakeholders and experts to examine the future of early care and education policy.
Atlantic Exchange featuring Helene Cooper and Jeffrey Goldberg
New York Times correspondent Helene Cooper will join The Atlantic’s Editor in Chief Jeffrey Goldberg to discuss her new book on work of Liberian President Ellen Johnson Sirleaf and her successful mobilization of a coalition built on the grassroots foundation of female voters.